Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer.
Ibiayi Dagogo-JackPablo MartinezBeow Y YeapChiara AmbrogioLorin A FerrisChristine LydonTom NguyenNicholas A JessopA John IafrateBruce E JohnsonJochen K LennerzAlice T ShawMark M AwadPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)
BRAF-mutant NSCLC is a heterogeneous disease that encompasses 3 distinct functional classes. Classes II and III have more aggressive clinical features leading to less favorable outcomes. The distinct biological characteristics of class II and III tumors suggest that class-specific therapies may be necessary to effectively target these molecular subsets.